Comparative Pharmacology
Head-to-head clinical analysis: METHADOSE versus TYLENOL W CODEINE NO 2.
Peer-Reviewed Evidence
Head-to-head clinical analysis: METHADOSE versus TYLENOL W CODEINE NO 2.
METHADOSE vs TYLENOL W/ CODEINE NO. 2
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Methadone is a mu-opioid receptor agonist; it also acts as an NMDA receptor antagonist and inhibits serotonin and norepinephrine reuptake, contributing to its analgesic and detoxification effects. It has a long half-life and reduces opioid craving and withdrawal symptoms.
Acetaminophen: Inhibits cyclooxygenase (COX) in the CNS, reducing prostaglandin synthesis, with weak peripheral COX inhibition. Codeine: Prodrug converted to morphine via CYP2D6; morphine acts as a mu-opioid receptor agonist, inhibiting ascending pain pathways and altering pain perception.
Oral: 20-40 mg once daily, titrated to effect; for opioid dependence, typical maintenance 80-120 mg/day. IV: 2.5-10 mg every 8-12 hours.
1 to 2 tablets (300 mg acetaminophen/15 mg codeine phosphate per tablet) orally every 4 hours as needed for pain; maximum 12 tablets per day.
None Documented
None Documented
Terminal elimination half-life range: 8–59 hours (mean ~20–35 hours). In chronic use, half-life may increase due to accumulation. Context: The long half-life supports once-daily dosing for opioid dependence but requires careful titration to avoid accumulation.
Acetaminophen: 2-3 hours. Codeine: 2.5-3.5 hours. In hepatic impairment, half-life of codeine may be prolonged.
Primarily renal (approximately 80%) as inactive metabolites, with about 20% eliminated via feces. Less than 10% excreted unchanged.
Renal: 70-80% as glucuronide and sulfate conjugates of acetaminophen, 5-10% as unchanged acetaminophen, and 5-10% as unchanged codeine. Biliary/fecal: minor, <5%.
Category C
Category D/X
Opioid Agonist
Opioid Agonist